Nom du produit:(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one

IUPAC Name:(3R)-4-[(2,4-dimethoxyphenyl)methyl]-3-methylpiperazin-2-one

CAS:1383146-20-0
Formule moléculaire:C14H20N2O3
Pureté:95%
Numéro de catalogue:CM131538
Poids moléculaire:264.33

Unité d'emballage Stock disponible Prix($) Quantité
CM131538-100mg in stock ƎȺ
CM131538-250mg in stock ȐǶŵ
CM131538-1g in stock ŵȡȡ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:1383146-20-0
Formule moléculaire:C14H20N2O3
Point de fusion:-
Code SMILES:O=C1NCCN(CC2=CC=C(OC)C=C2OC)[C@@H]1C
Densité:
Numéro de catalogue:CM131538
Poids moléculaire:264.33
Point d'ébullition:436.1±45.0°C at 760 mmHg
N° Mdl:MFCD22372628
Stockage:Store at room temperature.

Category Infos

Piperazines
Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

Column Infos

Fezolinetant
Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

Related Products